Table 3 Concomitant therapy in patients over the follow-up period
Follow-up time (months) | Yes | No | |||
|---|---|---|---|---|---|
Treatment | N | % | N | % | |
VDRA | 6 | 261 | 46 | 307 | 54.0 |
12 | 328 | 57.8 | 239 | 42.2 | |
18 | 335 | 67.5 | 161 | 32.5 | |
24 | 254 | 74.1 | 89 | 25.9 | |
30 | 162 | 75.7 | 52 | 24.3 | |
36 | 99 | 77.3 | 29 | 22.7 | |
Non-calcium-based phosphate binders | 6 | 223 | 39.3 | 345 | 60.7 |
12 | 300 | 52.9 | 267 | 47.1 | |
18 | 296 | 59.7 | 200 | 40.3 | |
24 | 222 | 64.7 | 121 | 35.3 | |
30 | 147 | 68.7 | 67 | 31.3 | |
36 | 90 | 70.3 | 38 | 29.7 | |
Calcium-based phosphate binders | 6 | 302 | 53.2 | 266 | 46.8 |
12 | 354 | 62.4 | 213 | 37.6 | |
18 | 339 | 68.3 | 157 | 31.7 | |
24 | 250 | 72.9 | 93 | 27.1 | |
30 | 161 | 75.2 | 53 | 24.8 | |
36 | 97 | 75.8 | 31 | 24.2 | |